Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 22 at 2:00 PM EDT

Register Free →

LABETALOL HYDROCHLORID

Active
SPE2DP-26-T-4201Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

Labetalol Hydrochloride Injection USP, 5 mg per mL in 40 mL vials, is being procured under solicitation SPE2DP-26-T-4201 with a total quantity of four vials, each containing 40 mL, for delivery within five days FOB destination. The item is regulated by the FDA and carries a non-extendable shelf life of 24 months as per RS001 requirements for Type I (Code M) pharmaceuticals. Packaging must comply with MIL-STD-2073-1E and the latest Medical Marking Standard No. 1, and all supplies must be labeled with the NDC number 00143-9623-01 under Hikma Pharmaceuticals USA Inc. The contract mandates strict zero variance in quantity and requires inspection and acceptance at the destination point. Technical and quality specifications are governed by the DLA Master List of Technical and Quality Requirements, and government identification must be removed from any non-accepted supplies. The contracting official must submit an EBS referral to the product specialist with full bidder and manufacturer details prior to award. The item is authorized under the DoD unit of issue VI, and procurement is managed by the Department of Defense through the Medical Supply Chain PHARM FSA.

General Info

Four 40 mL vials of Labetalol HCl Injection, NDC 00143-9623-01, deliverable in five days, FDA-regulated, 24-month shelf life.

Agency

Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSAView Agency

NAICS

325412 - Pharmaceutical Preparation ManufacturingView NAICS

Place of Performance

BLDG 1509 WEST 6TH STREET, FORT STEWART, GA, 31314-5185, US

Set-Aside

NONE

Documents

(1)

RFQ SPE2DP-26-T-4201 Medical Supply Chain Pharma FSA

PDFrfq

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
Contacts1 person available
OfficeUS
Organization / Agency
Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
View Agency Profile
Office AddressUS
Contacts

Full Description

Show more
LABETALOL HYDROCHLORIDE INJECTION
LABETALOL HYDROCHLORIDE INJECTION<(>,<)> USP. 5 MG PER ML<(>,<)> 40 ML.
1 VI = 40 ML. STORE AT MEDICAL CONTROLLED ROOM TEMPERATURE.
RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
RA001: THIS DOCUMENT INCORPORATES TECHNICAL AND/OR QUALITY REQUIREMENTS
(IDENTIFIED BY AN 'R' OR AN 'I' NUMBER) SET FORTH IN FULL TEXT IN THE
DLA MASTER LIST OF TECHNICAL AND QUALITY REQUIREMENTS FOUND ON THE WEB
AT:
http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx
FOR SIMPLIFIED ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE SOLICITATION ISSUE DATE OR THE AWARD DATE CONTROLS. FOR LARGE ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE RFP ISSUE DATE APPLIES UNLESS A SOLICITATION AMENDMENT INCORPORATES A FOLLOW-ON REVISION, IN WHICH CASE THE AMENDMENT DATE CONTROLS.
RQ011: REMOVAL OF GOVERNMENT IDENTIFICATION FROM NON-ACCEPTED SUPPLIES
INCLUDE RD003 OBJECT TEXT ID ST
This device or drug is regulated by the FDA. Note to Buyers: The contracting official shall send a referral in EBS to the product specialist for confirmation. Please include bidder name and bidder contact information, manufacturer name, manufacturer part number, and item description. RS016: Shelf-life requirement RS001 for a TYPE I (CODE M) item with a shelf life of 24 months (non-extendable) applies to this item.
Shall be marked IAW the latest edition of Medical Marking Standard No. 1 https://www.dla.mil/Logistics-Operations/Packaging/
HIKMA PHARMACEUTICALS USA INC. 32655 P/N NDC00143-9623-01
DLA issues this document using the DoD authorized unit of issue, please refer to the following URL to determine the corresponding ANSI X12 unit of issue.
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.dla.mil%2FPortals%2F104%2FDocuments% 2FDLMS%2FeApplications%2FLogDataAdmin%2FUnitofIssueandPurchaseUnit.xlsx&wdOrigin=BROWSELINK
CLIN PR PRLI UI QUANTITY UNIT PRICE TOTAL PRICE.
0001 7017513543 0001 VI 4.000
NSN/MATERIAL:6505012579990
DELIVERY (IN DAYS):0005
DELIVER FOB: DESTINATION
QTY VARIANCE: PLUS 0% MINUS 0%
INSPECTION POINT: DESTINATION
SPE2DP-26-T-4201
SECTION B
PR: 7017513543 PRLI: 0001 CONT’D
ACCEPTANCE POINT: DESTINATION
PREP FOR DELIVERY:
PKGING DATA MIL-STD-2073-1E
SPECIAL NSN/Part Number: 6505-01-257-9990 Quantity: 4 VI Purchase Request: 7017513543QTY: 4 Delivery: 5 days ADO

Similar Contracts

Same NAICS industry code

NAICS: 325412
New
DIBBS
Medical Chemical Formulation and ManufacturingThe contract involves the manufacture of a modified 0.125 percent sodium hypochlorite solution, known as Dakins Solution Quarter Strength, packaged in 480 mL bottles. The scope includes full formulation development, rigorous quality control protocols, batch-by-batch testing to ensure consistency and safety, and strict compliance with medical-grade standards to meet regulatory requirements for clinical use. All production activities must adhere to guidelines ensuring sterility, stability, and purity, as the final product is intended for medical applications requiring precise chemical concentrations and contamination-free packaging. The contract is classified as a subcontract under NAICS code 325412 for pharmaceutical and medicine manufacturing, issued by the Department of Defense through the Medical Supply Chain Pharm FSA. It was posted on July 20, 2026, with a response deadline of July 27, 2026, and the performance location is not specified, implying flexibility in manufacturing site selection as long as compliance and delivery standards are met. The solicitation is accessible through the DIBBS platform, and while no set-aside provisions or point of contact information is provided, bidders are expected to demonstrate proven capability in producing pharmaceutical-grade chemical solutions with validated quality systems and documented adherence to medical manufacturing regulations.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

about 13 hours ago

DEADLINE

in 6 days
View Details

More opportunities from Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA

Same awarding agency